PMID- 19659984
OWN - NLM
STAT- MEDLINE
DCOM- 20091102
LR  - 20210409
IS  - 1440-0960 (Electronic)
IS  - 0004-8380 (Linking)
VI  - 50
IP  - 3
DP  - 2009 Aug
TI  - Refractory subacute cutaneous lupus erythematosus successfully treated with 
      rituximab.
PG  - 202-6
LID - 10.1111/j.1440-0960.2009.00539.x [doi]
AB  - A 48-year-old woman presented with pruritic, scaly, annular plaques over her 
      upper back and chest that were clinically, serologically and histologically 
      characteristic of subacute cutaneous lupus erythematosus (SCLE). She failed to 
      respond to conventional treatment, which included high-dose hydroxychloroquine, 
      methotrexate, prednisolone, chloroquine, acitretin, thalidomide, dapsone and 
      azathioprine. Subsequently treated with intravenous rituximab 375 mg/m(2) weekly 
      for 4 weeks, she remained on adjuvant oral hydrochloroquine 600 mg daily and 
      topical clobetasol propionate 0.05% ointment as required. Clearing of annular 
      plaques was noted 8 weeks after the initial course of rituximab. By 12 weeks 
      there were no new lesions and only post-inflammatory hyperpigmentation remained. 
      Both hyper- and hypopigmentation, which is more common, are consistent with SCLE 
      lesion regression. Skin lesions recurred 11 months later; however, no further 
      lesions occurred after re-introduction of rituximab therapy. The treatment was 
      well tolerated. A maintenance regimen of rituximab, 375 mg/m(2) every 8 weeks for 
      2 years, was commenced 3 months after completing the second course of treatment, 
      with ongoing disease remission. Rituximab appears to have activity in refractory 
      SCLE and clinical trials are required to further assess this potential therapy.
FAU - Kieu, Violet
AU  - Kieu V
AD  - St Vincent's Hospital Melbourne, Fitzroy, VIC, Australia. violet.kieu@gmail.com
FAU - O'Brien, Timothy
AU  - O'Brien T
FAU - Yap, Lee-Mei
AU  - Yap LM
FAU - Baker, Christopher
AU  - Baker C
FAU - Foley, Peter
AU  - Foley P
FAU - Mason, Graham
AU  - Mason G
FAU - Prince, H Miles
AU  - Prince HM
FAU - McCormack, Christopher
AU  - McCormack C
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Australia
TA  - Australas J Dermatol
JT  - The Australasian journal of dermatology
JID - 0135232
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Immunologic Factors)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Antibodies, Monoclonal/*administration & dosage
MH  - Antibodies, Monoclonal, Murine-Derived
MH  - Biopsy, Needle
MH  - Disease Progression
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Resistance
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunohistochemistry
MH  - Immunologic Factors/*administration & dosage
MH  - Infusions, Intravenous
MH  - Lupus Erythematosus, Cutaneous/*drug therapy/immunology/*pathology
MH  - Middle Aged
MH  - Rituximab
MH  - Severity of Illness Index
MH  - Treatment Failure
MH  - Treatment Outcome
EDAT- 2009/08/08 09:00
MHDA- 2009/11/03 06:00
CRDT- 2009/08/08 09:00
PHST- 2009/08/08 09:00 [entrez]
PHST- 2009/08/08 09:00 [pubmed]
PHST- 2009/11/03 06:00 [medline]
AID - AJD539 [pii]
AID - 10.1111/j.1440-0960.2009.00539.x [doi]
PST - ppublish
SO  - Australas J Dermatol. 2009 Aug;50(3):202-6. doi: 
      10.1111/j.1440-0960.2009.00539.x.